The worldwide tobacco market is anticipated to succeed in $411.35 billion in output in 2025, supported by a compound annual development charge of two.37% by 2029. Conventional cigarette gross sales, nevertheless, proceed to face stress as laws tighten, with the World Well being Group reporting that 6.1 billion folks worldwide at the moment are lined by tobacco management measures.
On the similar time, dividend-focused traders stay drawn to established tobacco corporations for his or her regular money flows and dependable shareholder returns. On Aug 21, Altria Group (MO) introduced a 3.9% improve to its quarterly dividend, elevating it to $1.06 per share from $1.02, marking the corporate’s sixtieth dividend improve in 56 years. The brand new annualized dividend of $4.24 per share interprets right into a yield of 6.3%.
This transfer ties on to Altria’s dividend technique, which goals for mid-single-digit annual development by 2028, a plan that has persistently delivered even because the trade shifts towards reduced-risk merchandise. With regulatory pressures constructing and the long-term image for tobacco nonetheless unsure, does Altria’s enhanced dividend payout and Dividend King standing make it a compelling purchase at present ranges? Let’s take a more in-depth look.
Altria, the dad or mum firm behind Marlboro and different smokeable and oral tobacco merchandise, runs a enterprise that’s constructed on regular money move from its sturdy U.S. tobacco franchises whereas slowly transferring into reduced-risk alternate options. That stability has supported stable inventory positive aspects in 2025, with shares climbing practically 30% year-to-date (YTD).
www.barchart.com
On the valuation facet, MO inventory nonetheless appears to be like pretty cheap. It trades at a ahead price-to-earnings (P/E) ratio of about 12.5x in contrast with the sector common close to 17x, signaling modest development with out pricing in a lot of a premium.
Monetary outcomes from 2025 inform the complete story. Within the second quarter, web revenues got here in at $6.1 billion, down 1.7% from the prior 12 months, primarily as a result of declines in smokeable merchandise. Nonetheless, revenues web of excise taxes edged larger by 0.2% to $5.3 billion. Reported EPS fell 36.2% to $1.41, largely as a result of a one-time enhance in 2024 from the IQOS rights sale.
Stripping that out, adjusted EPS rose 8.3% to $1.44, pushed by larger working earnings and fewer shares excellent. For the primary half of the 12 months, revenues declined 3.6% to $11.4 billion, however adjusted EPS improved 7.2% to $2.67, helped by effectivity positive aspects, a decrease adjusted tax charge, and fewer shares. Reported EPS for the half slipped 40.2% to $2.04, reflecting impairments and acquisition-related prices, although these didn’t impression the adjusted backside line.
Considered one of Altria’s most essential development drivers is its push past cigarettes, and the on! nicotine pouch model continues to realize traction. In Q2 2025, shipments elevated 26.5% to 52.1 million cans, whereas its share of the oral tobacco class rose to eight.7%, up 0.7 proportion factors from a 12 months earlier. Contained in the pouch phase particularly, on! now holds a 17.9% share, giving Altria a stronger place in one of many few components of the trade nonetheless rising.
On the similar time, Altria is engaged on a fair greater step ahead with heated tobacco. By means of Horizon Improvements, its three way partnership with Japan Tobacco Worldwide, the corporate is getting ready to hunt FDA approval for its Ploom heated tobacco units in 2025. The partnership combines JTI’s system experience with Altria’s regulatory know-how and its broad U.S. distribution system. If accredited, Ploom may open up a brand new income stream by interesting to conventional people who smoke who’ve averted e‑vapor merchandise.
These efforts matter as a result of they strengthen Altria’s core identification as a regular dividend payer. The corporate has now lifted its payout for 57 years in a row, with the most recent improve bringing the quarterly dividend to $1.06 per share. The yield stands at about 6.03%, supported by a ahead payout ratio simply above 76%, exhibiting the dividend stays well-covered by money move.
Trying forward, administration has narrowed its 2025 full-year adjusted EPS steering to a spread of $5.35 to $5.45. That represents 3% to five% development in comparison with the 2024 base of $5.19. Analyst estimates are consistent with that concentrate on, with expectations for Q3 2025 at $1.42 versus $1.38 in the identical quarter a 12 months earlier, exhibiting modest however regular progress 12 months over 12 months.
Wall Road’s view on the inventory is much less easy. BofA Securities stored its “Purchase” ranking on Aug. 22, 2025, and raised its worth goal from $64 to $72, pointing to confidence in Altria’s smoke-free technique and reliable money flows. The broader analyst group, nevertheless, is extra cautious. Out of 15 surveyed, the consensus stays a stable “Maintain,” reflecting worries about whether or not declining cigarette gross sales will restrict future income development.
This divide is evident when taking a look at worth targets. The consensus imply goal for the inventory is $60, which is about 11% under Altria’s present worth.
So, do you have to purchase Altria after its newest dividend hike? If you happen to’re an income-focused investor, the case is evident: a 6%+ yield, 57 straight years of dividend will increase, and resilient money flows make MO one of the crucial dependable earnings performs round. However for development‑hungry traders, the story is trickier. Regulatory headwinds and flat top-line development restrict the inventory’s upside, and with the consensus worth goal sitting under present ranges, analysts don’t see a lot room for appreciation. Probably, shares will tread water close to present highs, rewarding traders by dividends moderately than dramatic worth positive aspects.
www.barchart.com
On the date of publication, Ebube Jones didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All data and knowledge on this article is solely for informational functions. This text was initially revealed on Barchart.com
Subscribe to Our Newsletter
Subscribe to our newsletter to get our newest articles instantly!
